Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone in adolescents with schizophrenia
NCT00088075Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Aug 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00088075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088075.